Influenza: Practice Essentials, Background, Pathophysiology - 0 views
-
szapata805 on 10 Sep 14"High-dose influenza vaccine appears to have the potential to prevent nearly one-quarter of all breakthrough influenza illnesses in seniors (≥65 y) compared with the standard-dose vaccine, according to results from a phase IIIb-IV double-blind, active-controlled trial.[3, 4] A total of 31,989 participants were randomly assigned to receive either a high dose (IIV3-HD) (60 μg of hemagglutinin per strain) or a standard dose (IIV3-SD) (15 μg of hemagglutinin per strain) of a trivalent, inactivated influenza vaccine. The multicenter trial was performed during the influenza seasons of 2011-2012 and 2012-2013 in Canada and the United States.[3, 4]"